How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) posted its quarterly earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06.

What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?

1 employees have rated Allena Pharmaceuticals Chief Executive Officer Louis Brenner, M.D. on Glassdoor.com . Louis Brenner, M.D. has an approval rating of 100% among the company's employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE) , Matinas BioPharma (MTNB) , VYNE Therapeutics (VYNE) , Dynavax Technologies (DVAX) , SCYNEXIS (SCYX) , Inovio Pharmaceuticals (INO) , TherapeuticsMD (TXMD) , VBI Vaccines (VBIV) , Acasti Pharma (ACST) and Miragen Therapeutics (MGEN) .

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Allena Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNA)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.02
▼
$0.16
52-Week Range: N/A

Volume: N/A
Average Volume: 15.69 million shs
Market Capitalization: $37,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Headlines Insider Trades Social Media

About Allena Pharmaceuticals Stock (NASDAQ:ALNA)

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

ALNA Stock News Headlines

November 5, 2023 | morningstar.com

Allena Pharmaceuticals Inc ALNAQ Stock Quote

August 28, 2023 | investing.com

Allena Pharmaceuticals Inc (ALNAQ)

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

May 6, 2023 | bizjournals.com

San Francisco Pharmaceuticals News

September 29, 2022 | reuters.com

ALNA.O

September 6, 2022 | wsj.com

Firm Retention Summary: Allena Pharmaceuticals Inc.

September 6, 2022 | finance.yahoo.com

Allena Pharmaceuticals Shares Fall After Filing For Bankruptcy

August 11, 2022 | finance.yahoo.com

Allena Pharma Needs To Raise Capital To Continue As A Going Concern

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

August 11, 2022 | marketwatch.com

Allena Pharmaceuticals Warns of Imminent Funding Need >ALNA

July 19, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

July 12, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

July 12, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

July 5, 2022 | apnews.com

Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

July 5, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

July 1, 2022 | uk.investing.com

Why Shares Of Allena Pharmaceuticals Are Skyrocketing Today

June 29, 2022 | investorplace.com

ALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%

May 16, 2022 | msn.com

Short Volatility Alert: Allena Pharmaceuticals

May 12, 2022 | investorplace.com

ALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceuticals Soars 100%

May 12, 2022 | seekingalpha.com

Nano cap stock Allena surges on heavy volume

May 4, 2022 | seekingalpha.com

Allena Pharmaceuticals $2.8M direct offering

May 4, 2022 | finance.yahoo.com

Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering

March 22, 2022 | seekingalpha.com

Allena downgraded to Neutral at B. Riley citing the end to lead clinical program

March 21, 2022 | finance.yahoo.com

Why Are Allena Pharma Shares Plunging Today

March 21, 2022 | seekingalpha.com

Allena extends losses on plans to end trial for lead asset and financial concerns

March 1, 2022 | finance.yahoo.com

Allena Pharmaceuticals, Inc. (ALNA)

January 29, 2022 | fool.com

Allena Pharmaceuticals, Inc.(ALNA)

See More Headlines

Receive ALNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/31/2022
Today: 12/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALNA
CUSIP: N/A
CIK: 1624658
Web: www.allenapharma.com
Phone: (617) 467-4577
Fax: 617-916-1871
Employees: 35
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-48,660,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -287.46%
Return on Assets: -146.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.58
Quick Ratio: 1.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.23 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 122,083,000
Free Float: 117,566,000
Market Cap: $37,000.00
Optionable: Not Optionable
Beta: 1.13

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Alexey L. Margolin Ph.D. (Age 69)
Co-Founder & Chairman
Comp: $70k
Dr. Louis Brenner M.B.A. (Age 52)
M.D., Pres, CEO & Director
Comp: $576.86k
Dr. Richard D. Katz (Age 58)
CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $400.67k
Mr. Robert Gallotto (Age 57)
Co-Founder & Strategic Adviser
Mr. Geoffrey A. Swire (Age 49)
Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer
Mr. Hugh Wight
Sr. VP of Technical Operations
Dr. Alicja Januszewicz Ph.D.
VP of People & Culture
Dr. David J. Clark (Age 57)
Chief Medical Officer

Key Competitors

View All Competitors

ALNA Stock Analysis - Frequently Asked Questions

How were Allena Pharmaceuticals' earnings last quarter?: Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) posted its quarterly earnings results on Thursday, March, 31st. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06.
What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO?: 1 employees have rated Allena Pharmaceuticals Chief Executive Officer Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among the company's employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Allena Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN).
When did Allena Pharmaceuticals IPO?: (ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

This page (NASDAQ:ALNA) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Allena Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNA)

About Allena Pharmaceuticals Stock (NASDAQ:ALNA)

ALNA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ALNA Stock Analysis - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info